NeuBase Therapeutics Inc
F:O7PA
NeuBase Therapeutics Inc
Accounts Payable
NeuBase Therapeutics Inc
Accounts Payable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Payable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
N
|
NeuBase Therapeutics Inc
F:O7PA
|
Accounts Payable
$260k
|
CAGR 3-Years
-44%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-6%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Accounts Payable
$33.6B
|
CAGR 3-Years
13%
|
CAGR 5-Years
12%
|
CAGR 10-Years
15%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Accounts Payable
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Accounts Payable
$20.9B
|
CAGR 3-Years
137%
|
CAGR 5-Years
71%
|
CAGR 10-Years
36%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Accounts Payable
$3.4B
|
CAGR 3-Years
124%
|
CAGR 5-Years
86%
|
CAGR 10-Years
47%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Accounts Payable
$6.8B
|
CAGR 3-Years
126%
|
CAGR 5-Years
70%
|
CAGR 10-Years
47%
|
|
NeuBase Therapeutics Inc
Glance View
NeuBase Therapeutics, Inc. is a biotechnology company, which engages in the development of drugs for patients with genetic neurological disorders. The company is headquartered in Pittsburgh, Pennsylvania and currently employs 33 full-time employees. The firm is focused on developing therapies to treat rare genetic diseases and cancers caused by mutant genes. The Company’s peptide-nucleic acid antisense oligonucleotide (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders. Its programs include NT0100, a PATrOL-enabled therapeutic program for systemic administration to target the mutant expansion in the HD messenger ribonucleic acid (mRNA) and NT0200, a PATrOL-enabled therapeutic program for systemic administration to target the mutant expansion in the myotonic dystrophy type one disease mRNA.
See Also
What is NeuBase Therapeutics Inc's Accounts Payable?
Accounts Payable
260k
USD
Based on the financial report for Sep 30, 2023, NeuBase Therapeutics Inc's Accounts Payable amounts to 260k USD.
What is NeuBase Therapeutics Inc's Accounts Payable growth rate?
Accounts Payable CAGR 10Y
-6%
Over the last year, the Accounts Payable growth was -86%. The average annual Accounts Payable growth rates for NeuBase Therapeutics Inc have been -44% over the past three years , -17% over the past five years , and -6% over the past ten years .
